2018 American Transplant Congress
Sirolimus Use Improves Cancer-Free Survival Following Transplantation: A Single Center 10-Year Analysis
Introduction:In previous published results, we showed that the use of Sirolimus-based immunosuppression regimens had equivalent patient and graft 10-year survival compared to historical controls maintained…2018 American Transplant Congress
Multi-Visceral Transplant in an HIV Positive Recipient – One Year Survival
Surgery, Indiana University School of Medicine, Indianapolis, IN.
Human immunodeficiency virus (HIV) is associated with hypercoagulability and thrombotic events. Highly active anti-retroviral therapy (HAART) has improved long term survival. More patients with HIV…2017 American Transplant Congress
Incidence, Recurrence and Long Term Survival Post Chemotherapy in Renal Transplant Recipients with Post Transplant Lymphoproliferative Disorder: Single Center Study.
Department of Renal Medicine, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom
Background: Majority of Post transplant lymphoproliferative disorders(PTLD) occur in the first year post solid organ transplant. The risk factors for development of PTLD include degree…2017 American Transplant Congress
Risk Factors for Post-Transplant Lymphoproliferative Disorders in Epstein-Barr Virus Mismatch Lung Transplant Recipients.
Brigham and Women's Hospital, Boston
Background: Post-transplant lymphoproliferative disorders (PTLD) are associated with significant morbidity and morality. Lung transplant patients appear to have higher rates of PTLD than other solid…2017 American Transplant Congress
Inhibition of Multiple Nodes in the PI3K/Akt/mTOR Pathway Synergistically Suppresses Epstein-Barr Virus B Cell Lymphomas.
Division of Abdominal Transplantation, Stanford School of Medicine, Palo Alto, CA
Treating post-transplant lymphoproliferative disorders (PTLD) remains a clinical challenge due to adverse effects such as graft rejection. mTOR inhibitors, including rapamycin (RAPA), have shown both…2017 American Transplant Congress
Genomic Diversity of Epstein-Barr Virus in Post-Transplant Lymphoproliferative Disorder.
Program in Immunology, Stanford University School of Medicine, Stanford, CA
Purpose: In transplant recipients, Epstein-Barr Virus (EBV) is associated with the development of B cell lymphomas in post-transplant lymphoproliferative disorder (PTLD). We used next-generation sequencing…2017 American Transplant Congress
Presence of Anellovirus Nucleic Acid Sequences in Involved Tissue Is Associated with Worse Patient Survival in Post-Transplant Lymphoproliferative Disorder.
Washington University in St Louis School of Medicine, St. Louis
Introduction: PTLD remain a feared complication of organ and tissue transplant, with high morbidity and mortality. While 50-80% of cases are strongly associated with Epstein-Barr…2017 American Transplant Congress
Rituximab Desensitization (DES) and Alemtuzumab Induction Significantly Reduced EBV Viremia and Post-Transplant Lymphoproliferative Disorder (PTLD) in HLA-Sensitized (HS) Kidney Transplant Patients.
Background: PTLD is a serious complication in KTx pts and is usually associated with EBV infection. Recent studies showed that rituximab treatment prior to Tx…2017 American Transplant Congress
Risk of Primary Central Nervous System Lymphoma in Solid Organ Transplant Recipients.
National Cancer Institute, Bethesda, MD
Background: Risk of primary central nervous system lymphoma (PCNSL) is greatly increased in immunosuppressed HIV-infected people. Case series describe PCNSL in solid organ transplant (SOT)…2017 American Transplant Congress
Post-Transplant Lymphoproliferative Disorder: Risk Analysis for Pancreas Transplant Patients.
Dept of Surgery, University of Minnesota, Minneapolis, MN
Objective: Determine incidence, risk factors, and impact of PTLD in pancreas transplantation (PTx).Methods: Retrospective review of all PTx performed between 7/25/1978 and 12/17/2015 at a…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- Next Page »